Physician profile
Junling Dong
NPI 1225449069
$590.93
in general payments reported to CMS, 2019-2025
13 companies · $99.37 in 2025
The $99.37 reported for 2025 was more than what a typical Neurocritical Care provider received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $47.61 · 2021: $34.23 · 2022: $38.59 · 2024: $91.75 · 2025: $99.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $91.92 | 2019 | |
| Janssen Biotech, INC. | $79.62 | 2025 | |
| Portola Pharmaceuticals, LLC | $71.23 | 2019 | |
| Genzyme Corporation | $71.20 | 2020-2022 | |
| Genentech USA, INC. | $60.76 | 2019-2020 | |
| Amgen INC. | $46.38 | 2019 | |
| Csl Behring | $38.81 | 2020-2024 | Kcentra |
| Boston Scientific Corporation | $32.23 | 2024 | Watchman Flx |
| Chiesi USA, INC. | $24.38 | 2024 | Cleviprex |
| Novartis Pharmaceuticals Corporation | $22.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.75 | 2025 | Ultomiris |
| Celgene Corporation | $16.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junling Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.